News

RhoVac’s co-founder Anders Ljungqvist has passed away

[Read more]

RhoVacs medgrundare Anders Ljungqvist har gått bort

[Read more]

Kallelse till extra bolagsstämma i RhoVac AB

Regulatory press release

[Read more]

RhoVac AB conducts conditional reverse takeover of Chosa ApS

Regulatory press release

[Read more]

RhoVac AB genomför villkorat omvänt förvärv av Chosa ApS

Regulatory press release

[Read more]

RhoVac AB presenterar delårsrapport Q3 2022

Regulatory press release

[Read more]

Rhovac board member resigns due to health reasons

Regulatory press release

[Read more]

Styrelseledamot i Rhovac AB avgår på grund av hälsoskäl

Regulatory press release

[Read more]

RhoVac AB ställer in planerad extra bolagsstämma

Regulatory press release

[Read more]

Kallelse till extra bolagsstämma i RhoVac AB

Regulatory press release

[Read more]

Board member Lars Hedbys takes over as acting CEO of RhoVac on 1 September

Regulatory press release

[Read more]

Styrelseledamot Lars Hedbys tillträder som tillförordnad VD i RhoVac 1 september

Regulatory press release

[Read more]

RhoVac AB presenterar delårsrapport Q2 2022

Regulatory press release

[Read more]

The board decides on first partial repayment of convertible loan

Regulatory press release

[Read more]

Styrelsen beslutar om en första delåter­betaling av konvertibellån

Regulatory press release

[Read more]

RhoVac's CEO, Anders Månsson, has tendered his resignation

Regulatory press release

[Read more]

RhoVacs VD, Anders Månsson, har lämnat in sin avskedsansökan

Regulatory press release

[Read more]

RhoVac terminates its stock liquidity provision service and announces the last day for trading in the convertible

Regulatory press release

[Read more]

RhoVac avslutar tjänst om likviditetsgaranti i aktien och meddelar om sista dag för handel med konvertibeln

Regulatory press release

[Read more]

RhoVac provides a status update and investigates a potentially accelerated repayment of the convertible loan

Regulatory press release

[Read more]

RhoVac ger statusuppdatering och undersöker förutsättningarna för en accelererad återbetalning av konvertibellånet

Regulatory press release

[Read more]

RhoVac’s phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint

Regulatory press release

[Read more]

RhoVacs fas IIb-studie, BRaVac, lyckades inte nå sin ”Primary Endpoint”

Regulatory press release

[Read more]

Pre-clinical findings support the potential use of RhoVac’s drug candidate, onilcamotide, across several cancers

Regulatory press release

[Read more]